Overcoming immunogenicity associated with the use of biopharmaceuticals
Authors:
- Michael G ToveyMTMichael G Tovey
- Julie LegrandJLJulie Legrand
- Christophe LallemandCLChristophe Lallemand
- 1 September 2011
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 4 (5) , 623-631
Abstract
The safety and efficacy of biopharmaceuticals can be severely impaired by their immunogenicity. A risk-based strategy should be used to assess immunogenicity on a case-by-case basis using standardized methods to correlate anti-drug antibody levels with clinical outcome. In silico and in vitro techniques allow putative T-cell epitopes to be identified and eliminated in candidate molecules while maintaining structure and function. Putative T-cell epitopes can be studied in the context of the HLA allotypes representative of the target population in vitro and in transgenic mice that express human HLA genes. Mice immune tolerant to human proteins allow the study of the effect of factors such as aggregation on the loss of immune tolerance. However, significant challenges remain in order to be able predict the immunogenicity of a therapeutic protein in a particular individual.Keywords
This publication has 44 references indexed in Scilit:
- Taking immunogenicity assessment of therapeutic proteins to the next levelBiologicals, 2011
- SVM-based prediction of linear B-cell epitopes using Bayes Feature ExtractionBMC Genomics, 2010
- Aggregated Recombinant Human Interferon Beta Induces Antibodies but No Memory in Immune-Tolerant Transgenic MicePharmaceutical Research, 2010
- Optimization algorithms for functional deimmunization of therapeutic proteinsBMC Bioinformatics, 2010
- Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studiesRegulatory Toxicology and Pharmacology, 2009
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology productsJournal of Pharmaceutical and Biomedical Analysis, 2008
- HLA-DRB1∗0401 and HLA-DRB1∗0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple SclerosisThe American Journal of Human Genetics, 2008
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-GalactoseNew England Journal of Medicine, 2008
- Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicityClinical Immunology, 2006
- Correlation between Factor VIII Genotype and Inhibitor Development in Hemophilia ASeminars in Thrombosis and Hemostasis, 2000